Drug Interaction Report

Octreotide and Lutetium Lu 177 Dotatate: Interaction Details

A pharmacist-reviewed analysis of the Octreotide and Lutetium Lu 177 Dotatate interaction: the documented clinical effects, severity rating, onset, mechanism, and management considerations, with cited references throughout.

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Octreotide

Bynfezia Mycapssa Mycapssa® Sandostatin
+

Lutetium Lu 177 Dotatate

No brand names on record
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
Updated Aug 8, 2026
Editorial policy · Data sources
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 380 documented Octreotide interactions, 363 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
Onset
unspecified
Evidence
theoretical
Severity
Major

What happens

Decreased lutetium Lu 177 dotatate efficacy

Interaction Deep Dive

Somatostatin analogs may interfere with lutetium Lu 177 dotatate efficacy due to competitive binding with somatostatin receptors. Appropriate short- and long-acting somatostatin analog administration must be followed before, during, and after lutetium Lu 177 dotatate administration. Before initiating lutetium Lu 177 dotatate, discontinue long-acting somatostatin analogs at least 4 weeks prior to administration of each lutetium Lu 177 dotatate dose. Administer short-acting octreotide as needed, but discontinue at least 24 hours prior to each lutetium Lu 177 dotatate dose. During treatment, administer long-acting octreotide 30 mg IM between 4 and 24 hours after each lutetium Lu 177 dotatate dose. Do not administer long-acting octreotide within 4 weeks of each subsequent lutetium Lu 177 dotatate dose. If needed, short-acting octreotide may be administered for symptomatic management during lutetium Lu 177 dotatate treatment, but must be withheld for at least 24 hours before each dose. After lutetium Lu 177 dotatate treatment, continue long-acting octreotide 30 mg IM every 4 weeks until disease progression or for up to 18 months after treatment initiation1.

Why it happens (mechanism)

Interference with the binding of lutetium Lu 177 dotatate to somatostatin receptors leading to decreased efficacy

Common questions

Can I take Octreotide and Lutetium Lu 177 Dotatate together?

Decreased lutetium Lu 177 dotatate efficacy Always confirm with your pharmacist or prescriber before making any change.

How serious is the Octreotide and Lutetium Lu 177 Dotatate interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Octreotide or Lutetium Lu 177 Dotatate need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (1)

  1. Product Information: LUTATHERA(R) intravenous injection, lutetium Lu 177 dotatate intravenous injection. Advanced Accelerator Applications USA Inc (per FDA), Millburn, NJ, 2018. DailyMed
Was this write-up helpful?
Octreotide

Keep reading about Octreotide

All Octreotide interactions (380) Octreotide drug information
Also serious with: Sparfloxacin Pimozide Saquinavir Piperaquine
Lutetium Lu 177 Dotatate

Keep reading about Lutetium Lu 177 Dotatate

All Lutetium Lu 177 Dotatate interactions (36)
Also serious with: Diflorasone Topical Hydrocortisone Ciclesonide Oral Inhalation Desonide
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

Octreotide + Activated Charcoal Adrafinil Cannabidiol (cbd) Cannabinol (cbn) Cannabis Coffee Charcoal Delta-9-tetrahydrocannabinol (thc) Ergot + 22 more

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.